Journals / Toraks Dergisi / 2003 / Cilt: 4 - Sayı: 3

Diagnostic value of multiple tumor marker analysis in lung cancer

Akciğer kanserinde çoklu tümör belirleyicisi analizi

Pages
248–259
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Multiple tumor marker analysis can exert useful tool for disease diagnosis and prediction of histological type in primary lung cancer.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The aim of this study was to evaluate the diagnostic value of multiple tumor marker analysis in lung cancer.
📊
Key Findings & Data:Nine tumor markers, neuron-specific enolase (NSE), total sialic acid (TSA), lipid-bound sialic acid (LSA), mucinous-like carcinoma associated antigen (MCA), carbohydrate antigen 125 (CA 125), CA19-9, ferritin (FER), carcinoembriyogenic antigen (CEA) and alfa-feto protein (AFP) levels were measured in 67 patients with newly diagnosed primary lung cancer, 31 patients with benign lung diseases and 30 healthy control.
💡
Conclusion & Impact:Multiple tumor marker analysis can exert useful tool for disease diagnosis and prediction of histological type in primary lung cancer.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Tümör belirteci · biyolojik · Diskriminant analizi

Abstract

The aim of this study was to evaluate the diagnostic value of multiple tumor marker analysis in lung cancer. Nine tumor markers, neuron-specific enolase (NSE), total sialic acid (TSA), lipid-bound sialic acid (LSA), mucinous-like carcinoma associated antigen (MCA), carbohydrate antigen 125 (CA 125), CA19-9, ferritin (FER), carcinoembriyogenic antigen (CEA) and alfa-feto protein (AFP) levels were measured in 67 patients with newly diagnosed primary lung cancer, 31 patients with benign lung diseases and 30 healthy control. Diagnostic efficacy of multiple marker combinations was evaluated with forward logistic regression (LR) analysis, and histological and stage groups were evaluated with discriminant analysis using SPSS software. In LR analysis, combination of CEA, LSA, MCA and TSA [Exp (B)=5.18, 95%CI=1.55-17.3; Exp (B)=1.37, 95%CI=1.09-1.74; Exp (B)=1.10, 95%CI=1.01-1.21; Exp (B)=1.10, 95%CI=1.04-1.16, respectively] were found to detect lung cancer in 94.9% of the cases accurately. In discriminant analysis (W ilks' Lambda=0.68, p<0.01), NSE positivity in small cell lung cancer (SCLC) (Wilks' Lambda=0.92, p<0.05) and FER positivity in non-SCLC (Wilks' Lambda=0.91, p<0.05) were discriminative. The combination of these two markers were found to predict the tumor type in 77.6% of the cases accurately. In analysis of stage discrimination, there was no significant combination. Multiple tumor marker analysis can exert useful tool for disease diagnosis and prediction of histological type in primary lung cancer.

Özet

Bu çalışma, akciğer kanseri tanısında çoklu tümör belirleyicisi analizinin değerini belirlemek amacıyla yapıldı. Dokuz tümör belirleyicisi, nöron-spesifik enolaz (NSE), total sialik asit (TSA), lipid bağlı sialik asit (LSA), müsinöz benzeri karsinomla ilişkili antijen (MCA), karbonhidrat antijen 125 (CA 125), CA19-9, ferritin (FER), karsinoembriyojenik antijen (CEA) ve alfa-feto protein (AFP) düzeyleri yeni tanı konulmuş 67 akciğer kanseri, 31 benign akciğer hastalığı olgusu ve 30 sağlıklı kontrolde ölçüldü. Çoklu belirleyici kombinasyonlarının tanısal etkinliği, SPSS programında ileriye yönelik (forward) lojistik regresyon (LR) analizi ile, histolojik ve evre gruplarını ayırmadaki etkinliği ise diskriminant analizi ile değerlendirildi. LR analizinde CEA, LSA, MCA ve TSA kombinasyonunun akciğer kanserini %94.9 doğrulukla saptayabildiği bulundu [CEA: Exp (B)=5.18, %95 GA =1.55-17.3; LSA: Exp (B)=1.37, %95 GA=1.091.74; MCA: Exp (B)=1.1; %95 GA=1.01-1.21; TSA: Exp (B)=1.1, %95 GA=1.04-1.16]. Disk riminant analizinde (Wilks' Lambda=0.68, p<0.01), NSE pozitifliğinin küçük hücreli akciğer kanseri (KHAK) için (Wilks' Lambda=0.92, p<0.05), FER pozitifliğinin KHDAK için (Wilks' Lambda=0.92, p<0.05) ayırıcı olduğu saptandı. Bu iki tümör belirleyicisinin kombine kullanımı tümör tipini %77.6 oranında doğru tahmin etti. Evre gruplarının ayrımı için yapılan analizlerde anlamlı bir tümör belirleyici kombinasyonu saptanmadı. Çoklu tümör belirleyicisi analizi primer akciğer kanseri olgularında tanı ve histolojik tip tahmini için yararlı bir araç olabilir.

🔖

Cite This Article

KARLIKAYA, C., ERDOĞAN, S., AKKOÇLU, A., OKTAY, G., GÜNER, G., UÇAN, E. S., ÇIMRIN, A. H. (2003). Diagnostic value of multiple tumor marker analysis in lung cancer. Toraks Dergisi, Cilt: 4 - Sayı: 3, 248–259. https://ajindex.com/articles/367995

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (17)

  1. ) Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J Cancer 1993
  2. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997
  3. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. CA Cancer J Clin 1999
  4. 31, 1. 4) Smith RA, Glynn TJ. Epidemiology of lung cancer. Radiol Clin North Am 2000
  5. Halilçolar H, Tatar D, Ertuğrul G, Çakan A, Acıtaş M, Kömürcüoğlu B. Epidemiyoloji. In: Akkoclu A, Öztürk C, eds. Akciğer Kanseri, Multidisipliner Yaklaşım. Ankara: Toraks Derneği, 1999
  6. Fidaner C, Eser SY, Parkin DM. Incidence in Izmir in 1993-1994: first results from Izmir Cancer Registry. Eur J Cancer 2001
  7. Goksel T, Akkoclu A. Pattern of lung cancer in Turkey, 1994-1998. Respiration 2002
  8. Malkin A. Tumor markers. In: Tannock IF, Hill RP, eds. The Basic Science of Oncology. New York: McGraw-Hill Inc., 1992
  9. Mountain CF. A new international staging system for lung cancer. Chest 1986
  10. 225S-33S. 10) Mountain CF. Lung cancer staging classification. Clin Chest Med 1993
  11. Sydow G. A simplified quick method for determination of sialic acid in serum. Biomed Biochim Acta 1985
  12. Katopodis N, Stock CC. Improved method to determine lipid bound sialic acid in plasma or serum. Res Commun Chem Pathol Pharmacol. 1980
  13. Dawson-Saunders B, Trapp RG. Basic and clinical biostatistics / Beth Dawson-Saunders, Robert G. Trapp. Norwalk, Conn.: Appleton & Lange, 1990. 14) Boyd NF. Guide to studies of diagnostic tests, prognosis, and treatment. In: Tannock IF, Hill RP, eds. New York: McGraw-Hill, 1992. 15) Sümbüloğlu K, Sümbüloğlu V. Biyoistatistik. Ankara: Hatiboğlu Yayınevi, 1989. 16) Strauss GM, Skarin AT. Use of tumor markers in lung cancer. Hematol Oncol Clin North Am. 1994
  14. Lombardi C, Tassi GF, Pizzocolo G, Donato F. Clinical significance of a multiple biomarker assay in patients with lung cancer. A study with logistic regression analysis. Chest 1990
  15. Ferrigno D, Buccheri G, Biggi A. Serum tumour markers in lung cancer: history, biology and clinical applications. Eur Respir J. 1994
  16. 18697. 19) Carney DN, Marangos PJ, Ihde DC et al. Serum neuron-specific enolase: a marker for disease extent and response to therapy of small-cell lung cancer. Lancet 1982
  17. Akoun GM, Scarna